Selected research
Industry Research
Intravenous (IV) Iron Drugs Industry Research Report 2026
Market perspective
The global Intravenous (IV) Iron Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Intravenous (IV) Iron Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Intravenous (IV) Iron Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Intravenous (IV) Iron Drugs include Takeda Pharmaceutical, Sanofi US, Pharmacosmos, Luitpold Pharmaceuticals, Dalichi Sankyo, AMAG Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Intravenous (IV) Iron Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intravenous (IV) Iron Drugs Market by Company
Takeda Pharmaceutical
Sanofi US
Pharmacosmos
Luitpold Pharmaceuticals
Dalichi Sankyo
AMAG Pharmaceuticals
Allergan
Intravenous (IV) Iron Drugs Segment by Type
Ferric Carboxymaltose
Iron Dextran
Iron Sucrose
Others
Intravenous (IV) Iron Drugs Segment by Application
Gynecology & Obstetrics
Nephrology
Gastroenterology
Cardiology
Oncology
Others
Intravenous (IV) Iron Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous (IV) Iron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous (IV) Iron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous (IV) Iron Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Intravenous (IV) Iron Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Intravenous (IV) Iron Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Intravenous (IV) Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ferric Carboxymaltose
- Iron Dextran
- Iron Sucrose
- Others
Applications
- Gynecology & Obstetrics
- Nephrology
- Gastroenterology
- Cardiology
- Oncology
- Others
Companies covered
- Takeda Pharmaceutical
- Sanofi US
- Pharmacosmos
- Luitpold Pharmaceuticals
- Dalichi Sankyo
- AMAG Pharmaceuticals
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Intravenous (IV) Iron Drugs Market Size (2021-2032)
- 2.2.2 Global Intravenous (IV) Iron Drugs Sales (2021-2032)
- 2.2.3 Global Intravenous (IV) Iron Drugs Market Average Price (2021-2032)
- 2.3 Intravenous (IV) Iron Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ferric Carboxymaltose
- 2.3.3 Iron Dextran
- 2.3.4 Iron Sucrose
- 2.3.5 Others
- 2.4 Intravenous (IV) Iron Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gynecology & Obstetrics
- 2.4.3 Nephrology
- 2.4.4 Gastroenterology
- 2.4.5 Cardiology
- 2.4.6 Oncology
- 2.4.7 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Intravenous (IV) Iron Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Intravenous (IV) Iron Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Intravenous (IV) Iron Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Intravenous (IV) Iron Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Intravenous (IV) Iron Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Intravenous (IV) Iron Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Intravenous (IV) Iron Drugs, Product Type & Application
- 3.8 Global Manufacturers of Intravenous (IV) Iron Drugs, Established Date
- 3.9 Global Intravenous (IV) Iron Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical
- 4.1.1 Takeda Pharmaceutical Company Information
- 4.1.2 Takeda Pharmaceutical Business Overview
- 4.1.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceutical Recent Developments
- 4.2 Sanofi US
- 4.2.1 Sanofi US Company Information
- 4.2.2 Sanofi US Business Overview
- 4.2.3 Sanofi US Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi US Intravenous (IV) Iron Drugs Product Portfolio
- 4.2.5 Sanofi US Recent Developments
- 4.3 Pharmacosmos
- 4.3.1 Pharmacosmos Company Information
- 4.3.2 Pharmacosmos Business Overview
- 4.3.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pharmacosmos Intravenous (IV) Iron Drugs Product Portfolio
- 4.3.5 Pharmacosmos Recent Developments
- 4.4 Luitpold Pharmaceuticals
- 4.4.1 Luitpold Pharmaceuticals Company Information
- 4.4.2 Luitpold Pharmaceuticals Business Overview
- 4.4.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
- 4.4.5 Luitpold Pharmaceuticals Recent Developments
- 4.5 Dalichi Sankyo
- 4.5.1 Dalichi Sankyo Company Information
- 4.5.2 Dalichi Sankyo Business Overview
- 4.5.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dalichi Sankyo Intravenous (IV) Iron Drugs Product Portfolio
- 4.5.5 Dalichi Sankyo Recent Developments
- 4.6 AMAG Pharmaceuticals
- 4.6.1 AMAG Pharmaceuticals Company Information
- 4.6.2 AMAG Pharmaceuticals Business Overview
- 4.6.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
- 4.6.5 AMAG Pharmaceuticals Recent Developments
- 4.7 Allergan
- 4.7.1 Allergan Company Information
- 4.7.2 Allergan Business Overview
- 4.7.3 Allergan Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Allergan Intravenous (IV) Iron Drugs Product Portfolio
- 4.7.5 Allergan Recent Developments
5 Global Intravenous (IV) Iron Drugs Market Scenario by Region
- 5.1 Global Intravenous (IV) Iron Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Intravenous (IV) Iron Drugs Sales by Region: 2021-2032
- 5.2.1 Global Intravenous (IV) Iron Drugs Sales by Region: 2021-2026
- 5.2.2 Global Intravenous (IV) Iron Drugs Sales by Region: 2027-2032
- 5.3 Global Intravenous (IV) Iron Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Intravenous (IV) Iron Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Intravenous (IV) Iron Drugs Revenue by Region: 2027-2032
- 5.4 North America Intravenous (IV) Iron Drugs Market Facts & Figures by Country
- 5.4.1 North America Intravenous (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
- 5.4.3 North America Intravenous (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Intravenous (IV) Iron Drugs Market Facts & Figures by Country
- 5.5.1 Europe Intravenous (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Intravenous (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Intravenous (IV) Iron Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Intravenous (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Intravenous (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Intravenous (IV) Iron Drugs Market Facts & Figures by Country
- 5.7.1 South America Intravenous (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
- 5.7.3 South America Intravenous (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Intravenous (IV) Iron Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Intravenous (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Intravenous (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Intravenous (IV) Iron Drugs Sales by Type (2021-2032)
- 6.1.1 Global Intravenous (IV) Iron Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Intravenous (IV) Iron Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Intravenous (IV) Iron Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Intravenous (IV) Iron Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Intravenous (IV) Iron Drugs Sales by Application (2021-2032)
- 7.1.1 Global Intravenous (IV) Iron Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Intravenous (IV) Iron Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Intravenous (IV) Iron Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Intravenous (IV) Iron Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Intravenous (IV) Iron Drugs Value Chain Analysis
- 8.1.1 Intravenous (IV) Iron Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Intravenous (IV) Iron Drugs Production Mode & Process
- 8.2 Intravenous (IV) Iron Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Intravenous (IV) Iron Drugs Distributors
- 8.2.3 Intravenous (IV) Iron Drugs Customers
9 Global Intravenous (IV) Iron Drugs Analyzing Market Dynamics
- 9.1 Intravenous (IV) Iron Drugs Industry Trends
- 9.2 Intravenous (IV) Iron Drugs Industry Drivers
- 9.3 Intravenous (IV) Iron Drugs Industry Opportunities and Challenges
- 9.4 Intravenous (IV) Iron Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst